ANI Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes prescription therapeutics across Rare Disease, Generics, and Brands. Its portfolio includes specialty products such as Cortrophin Gel, ILUVIEN, and YUTIQ, alongside a broader generics business supported by its own manufacturing footprint in Minnesota and New Jersey.
22,9 %
8,9 %
+43,8 %
2.71
2.19
| % | |
|---|---|
| Rare Disease and Brands | 53% Includes Cortrophin Gel, ILUVIEN, YUTIQ, and other branded specialty products sold through limited-distribution channels. |
| Generics | 44% Includes generic prescription pharmaceuticals sold primarily through wholesalers, retailers, and group purchasing organizations. |
| Royalties and Other Pharmaceutical Services | 3% Includes royalty income and other service revenue tied to pharmaceutical commercialization and partnerships. |
ANI sells mainly to pharmaceutical distribution intermediaries, specialty pharmacies, retail chains, and healthcare...
Buy generic and branded products in bulk for downstream distribution; important because ANI relies on a concentrated U.S. channel structure.
Dispense rare disease products such as Cortrophin Gel to eligible patients and support limited-distribution commercialization.
Purchase generic and branded medicines for broad consumer access through national pharmacy networks.
Buy and administer ILUVIEN and other specialty products in clinical settings, especially in ophthalmology.
Influence formulary access, rebates, and pricing terms that affect realized revenue and market penetration.
ANI is headquartered and primarily operates in the United States, where most of its manufacturing, commercialization,...
ANI's strategy centers on expanding its rare disease and specialty franchise while maintaining a cash-generative...
Higher-value specialty products can improve growth and diversify away from commoditized generics pricing.
The acquisition adds products, international channels, and a stronger specialty platform.
Owning manufacturing capacity supports product launches and reduces dependence on third parties.
ANI seeks additional products and assets to diversify revenue and support growth.
ANI faces concentration risk from a small number of large customers and channel partners, which can pressure pricing...
A small number of wholesalers and distributors account for a large share of revenue, so lost business or renegotiated terms would materially affect sales.
Generics compete mainly on price, contract terms, and service levels, which can compress margins and reduce volumes.
Specialty products must gain and sustain market acceptance to offset generics volatility.
Limited API suppliers and third-party manufacturers can cause delays, shortages, or compliance issues.
Pharmaceutical operations are exposed to FDA, reimbursement, anti-kickback, and foreign regulatory regimes.
Indebtedness and restrictive covenants can limit cash flow flexibility and trigger acceleration if breached.
ANIP · Pharmaceutical Preparations
ANI Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes prescription therapeutics across Rare Disease, Generics, and Brands.
ANTX · Pharmaceutical Preparations
ANVI · Retail-Food Stores
CNSP · Pharmaceutical Preparations
SOBI.ST · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
ZLAB · Pharmaceutical Preparations
Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for oncology, immunology, neuroscience, and infectious diseases.
: 11/08/2026